Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05896566
Other study ID # IBCSG 67-22
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 23, 2024
Est. completion date June 1, 2026

Study information

Verified date June 2024
Source ETOP IBCSG Partners Foundation
Contact Heidi Roschitzki, PhD
Phone +41 31 511 94 00
Email heidi.roschitzki@etop.ibcsg.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PREcoopERA is a randomized (2:2:1), multicenter, open-label, three-arm (A, B, C), Window-of-Opportunity (WOO) trial to evaluate the activity and safety of giredestrant (A) versus giredestrant plus triptorelin (B) versus anastrozole plus triptorelin (C).


Description:

The primary objectives are: - to determine if 4 weeks of giredestrant plus triptorelin provides greater anti-proliferative activity than anastrozole plus triptorelin among premenopausal patients with ER-positive/HER2-negative operable invasive breast cancer. - to determine if 4 weeks of giredestrant without triptorelin provides anti-proliferative activity that is similar (non-inferior) to giredestrant plus triptorelin among premenopausal patients with ER-positive/HER2-negative operable invasive breast cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 220
Est. completion date June 1, 2026
Est. primary completion date June 1, 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Premenopausal women age =18 years, premenopausal status defined as: Estradiol (E2) in the premenopausal range (according to institution parameters) or Patient has been menstruating regularly during the 6 months prior to screening and has not used any form of hormonal contraception or any other hormonal treatments during this time. - Histologically confirmed, operable invasive breast carcinoma. - Eligible for upfront breast conservative surgery or upfront mastectomy: stage I, stage II or operable stage III (excludes T4) (AJCC Cancer Staging Manual 8th edition 2017).46 Tumor size must be =1.0 cm Multicentric and multifocal tumors and bilateral breast cancers are allowed but investigators must ensure the same tumor foci is biopsied pre-treatment and post-treatment (e.g., via clipping of the biopsied tumor foci). - Documented estrogen receptor (ER)-positive tumor in accordance to ASCO/CAP guidelines (Allison et al. 2020),47 assessed locally and defined as =1% of tumor cells stained positive. - Documented human epidermal growth factor receptor-2 (HER2)-negative tumor in accordance to 2018 ASCO/CAP guidelines (Wolff et al. 2018)48, as determined per local assessment. - Ki 67 =10% in diagnostic biopsy as determined per local assessment. - Eastern Cooperative Oncology Group Performance Status 0-1. - Resting heart rate =40 bpm. - Normal hematologic status - Normal renal function - Normal liver function - INR <1.5× ULN and PTT <1.5x ULN Except for patients receiving anticoagulation therapy. For patients receiving warfarin, a stable INR between 2 and 3 is required. For patients receiving heparin, PTT between 1.5 and 2.5 x ULN (or value before patient started heparin treatment) is required. If anticoagulation therapy is required for a prosthetic heart valve, stable INR between 2.5 and 3.5 is permitted. - Negative serum or urine beta HCG pregnancy test within 5 weeks prior to randomization. Pregnancy test will be repeated on day 1, before the first dose of WOO treatment. Women of childbearing potential must use highly effective contraceptive methods during the treatment period and for 10 days after the final dose. - Written Informed Consent (IC) must be signed and dated by the patient and the Investigator prior to randomization. - The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines. - The patient agrees to the submission of tumor (diagnostic pre-treatment core biopsy and post-treatment re-biopsy) and blood samples for central pathology review (CPR) and for translational studies as part of this protocol. Exclusion Criteria: - Stage IV (metastatic) breast cancer. - Inflammatory breast cancer (cT4d). - Previous systemic or local treatment for the primary breast cancer currently under investigation. - Received any GnRH/LHRH analog within 12 months prior to randomization - Major surgery within 4 weeks prior to randomization. - Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including hepatitis. - Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. - History of documented hemorrhagic diathesis, coagulopathy, or thromboembolism. - Active cardiac disease or history of cardiac dysfunction, including any of the following: History or presence of symptomatic bradycardia or resting heart rate <50 bpm at screening. Patients on stable dose of a beta-blocker or calcium channel antagonist for pre-existing baseline conditions (e.g., hypertension) may be permitted if resting heart rate is =50 bpm. History of angina pectoris, symptomatic pericarditis, myocardial infarction, or any cardiac arrhythmias (e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality) within 12 months prior to study entry History of documented congestive heart failure (New York Heart Association Class II-IV) or cardiomyopathy Left ventricular ejection fraction <50% as determined by multiple-gated acquisition scan or echocardiogram QT interval corrected through use of Fridericia's formula (QTcF) >470 ms based on mean value of triplicate ECGs, history of long or short QT syndrome, Brugada syndrome or known history of corrected QT interval prolongation, or torsades de pointes History or presence of an abnormal ECG that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, sick sinus syndrome, or evidence of prior myocardial infarction - History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of long QT syndrome. - Current treatment with medications that are well known to prolong the QT interval. - Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to initiation of study treatment. - Known issues with swallowing oral medication. - Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or major upper gastrointestinal surgery including gastric resection. - Serious infection requiring oral or IV antibiotics, or other clinically significant infection within 14 days prior to screening. - Any active tumor of non-breast-cancer histology. - Women who are pregnant or in the period of lactating. - Any concurrent disease or serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study. - Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. - Contraindications or known hypersensitivity to the trial medication or excipients. - Treatment with any investigational agents within 30 days prior to expected start of trial treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Giredestrant
Giredestrant: 30 mg daily, PO from day 1 until the day of re-biopsy/surgery.
Triptorelin
Triptorelin: 3.75 mg IM on day 1. Note: If re-biopsy/surgery cannot be done on day 29 (±3 days) from the first injection, then a second dose of triptorelin should be given on day 29 (±3 days).
Anastrozole
Anastrozole: 1 mg daily, PO from day 1 until the day of re-biopsy/surgery.

Locations

Country Name City State
France Gustave Roussy Cancer Center Villejuif
Germany HELIOS Klinikum Berlin Buch Berlin
Germany Praxisklinik Krebsheilkunde formerly MediOnko-Institut GbR Berlin
Germany KEM / Kliniken Essen Mitte Essen
Germany Klinikum der J. W. Goethe Universität Frankfurt
Germany Universitätsklinikum Schleswig-Holstein Kiel
Germany St. Elisabeth Krankenhaus Leipzig
Germany Universitätsklinikum Mannheim GmbH Mannheim
Germany Klinikum Südstadt Rostock
Germany Universitätsklinikum Ulm Ulm
Germany Helios Klinikum Wuppertal GmbH Wuppertal
Hungary National Institute of Oncology Budapest
Ireland Cork University Hospital Cork
Ireland St. James Hospital Dublin
Ireland University Hospital Galway Galway
Italy Clinica Oncologica AOU Riuniti Ancona Ancona
Italy Humanitas Gavazzeni Bergamo
Italy ASL BR Azienda Sanitaria Locale Brindisi
Italy IRCCS Ospedale Policlinico San Martino Genova
Italy Istituto oncologico romagnolo per lo studio dei tumori "Dino Amadori" Meldola
Italy Istituto Europeo di Oncologia Milano
Italy AOU maggiore della carita Novara
Italy Istituti Clinici Scientifici Maugeri SpA-SB Pavia
Italy Azienda USL Toscana Centro Prato
Italy Rimini Oncology department Rimini
Italy Fondazione Policlinico Gemelli Medical Oncology Unit Roma
Italy Policlinico universitario Agostino Gemelli IRCCS Rome Roma
Spain Complejo Hospitalario Universitario Badajoz Badajoz
Spain Institut Catala D'oncologia ICO-Badalona Badalona
Spain Institut Catala d'Oncologia - Hospitalet Barcelona
Spain H.U. Arnau de Vilanova de Lleida Lleida
Spain CIOCC (Centro Integral Oncológico Clara Campal) Madrid
Spain Fundación Jiménez Díaz Madrid
Spain Hospital Universitari Son Espases Palma De Mallorca
Spain H. la Fé Valencia
Sweden Sahlgrenska Comprehensive Cancer Center Gothenburg
Switzerland Kantonsspital Baden AG Baden
Switzerland Praxis Dr. Thorn, Praxis fur ambulante Tumortherapie (Praxis Thorn (Bethesda)) Basel
Switzerland Onc Inst of Southern Switzerland (IOSI) Bellinzona
Switzerland Centre du Sein (Hopital Fribourgeois-Freiburger Spital) Fribourg
Switzerland La Chaux-de-fonds, RH Neuchatelois (Hopital Les Cadolles) La Chaux-de-Fonds
Switzerland St. Anna Hirslanden Luzern
Switzerland Brustzentrum Thurgau ( Spital AG) Thurgau
Switzerland Universitiy Hospital Zurich Zürich

Sponsors (2)

Lead Sponsor Collaborator
ETOP IBCSG Partners Foundation Hoffmann-La Roche

Countries where clinical trial is conducted

France,  Germany,  Hungary,  Ireland,  Italy,  Spain,  Sweden,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Ki 67 The primary endpoint is the change in Ki 67 (Ki 67-labeling index, the percentage immunostaining cells measured by IHC in central laboratory) between the pre-treatment tumor biopsy and a post-treatment tumor re-biopsy (analyzed on the natural logarithm scale). From date of randomisation until 29 ±3 days post-randomisation
Secondary Complete cell cycle arrest (CCCA) Complete cell cycle arrest (CCCA), defined as Ki 67 =2.7% on the post -treatment tumor re-biopsy on day 29 (±3 days), by visual image analysis. From date of randomisation until 29 ±3 days post-randomisation
Secondary Adverse events according to CTCAE v5.0 Record all AEs (including SAEs and AESIs) and assign the appropriate grade according to the CTCAE v5.0. From the date of enrolment until last patient last visit (approximately 28 months after randomisation of the first patient)]
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A